168 related articles for article (PubMed ID: 30566834)
1. Mitochondria Targeting and Destabilizing Hyaluronic Acid Derivative-Based Nanoparticles for the Delivery of Lapatinib to Triple-Negative Breast Cancer.
Lee SY; Cho HJ
Biomacromolecules; 2019 Feb; 20(2):835-845. PubMed ID: 30566834
[TBL] [Abstract][Full Text] [Related]
2. CD44 targeting hyaluronic acid coated lapatinib nanocrystals foster the efficacy against triple-negative breast cancer.
Agrawal S; Dwivedi M; Ahmad H; Chadchan SB; Arya A; Sikandar R; Kaushik S; Mitra K; Jha RK; Dwivedi AK
Nanomedicine; 2018 Feb; 14(2):327-337. PubMed ID: 29129754
[TBL] [Abstract][Full Text] [Related]
3. Co-delivery of gambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI-PLGA nanoparticles for the treatment of triple negative breast cancer.
Wang S; Shao M; Zhong Z; Wang A; Cao J; Lu Y; Wang Y; Zhang J
Drug Deliv; 2017 Nov; 24(1):1791-1800. PubMed ID: 29172759
[TBL] [Abstract][Full Text] [Related]
4. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.
Wan X; Zheng X; Pang X; Zhang Z; Jing T; Xu W; Zhang Q
Int J Pharm; 2015 Apr; 484(1-2):16-28. PubMed ID: 25700543
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronic acid-coated pH sensitive poly (β-amino ester) nanoparticles for co-delivery of embelin and TRAIL plasmid for triple negative breast cancer treatment.
Xu Y; Liu D; Hu J; Ding P; Chen M
Int J Pharm; 2020 Jan; 573():118637. PubMed ID: 31550511
[TBL] [Abstract][Full Text] [Related]
6. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
[TBL] [Abstract][Full Text] [Related]
7. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
8. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
[TBL] [Abstract][Full Text] [Related]
9. Unveiling the potential of ursolic acid modified hyaluronate nanoparticles for combination drug therapy in triple negative breast cancer.
Sharma R; Yadav V; Jha S; Dighe S; Jain S
Carbohydr Polym; 2024 Aug; 338():122196. PubMed ID: 38763723
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain.
Wan X; Zheng X; Pang X; Pang Z; Zhao J; Zhang Z; Jiang T; Xu W; Zhang Q; Jiang X
Oncotarget; 2016 Jun; 7(23):34038-51. PubMed ID: 27086917
[TBL] [Abstract][Full Text] [Related]
11. Delivery of thymoquinone through hyaluronic acid-decorated mixed Pluronic® nanoparticles to attenuate angiogenesis and metastasis of triple-negative breast cancer.
Bhattacharya S; Ghosh A; Maiti S; Ahir M; Debnath GH; Gupta P; Bhattacharjee M; Ghosh S; Chattopadhyay S; Mukherjee P; Adhikary A
J Control Release; 2020 Jun; 322():357-374. PubMed ID: 32243981
[TBL] [Abstract][Full Text] [Related]
12. Boronic acid-tethered amphiphilic hyaluronic acid derivative-based nanoassemblies for tumor targeting and penetration.
Jeong JY; Hong EH; Lee SY; Lee JY; Song JH; Ko SH; Shim JS; Choe S; Kim DD; Ko HJ; Cho HJ
Acta Biomater; 2017 Apr; 53():414-426. PubMed ID: 28216300
[TBL] [Abstract][Full Text] [Related]
13. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.
Liu CY; Hu MH; Hsu CJ; Huang CT; Wang DS; Tsai WC; Chen YT; Lee CH; Chu PY; Hsu CC; Chen MH; Shiau CW; Tseng LM; Chen KF
Oncotarget; 2016 Feb; 7(8):9135-49. PubMed ID: 26824320
[TBL] [Abstract][Full Text] [Related]
14. GE11 peptide modified and reduction-responsive hyaluronic acid-based nanoparticles induced higher efficacy of doxorubicin for breast carcinoma therapy.
Hu D; Mezghrani O; Zhang L; Chen Y; Ke X; Ci T
Int J Nanomedicine; 2016; 11():5125-5147. PubMed ID: 27785019
[TBL] [Abstract][Full Text] [Related]
15. Treating metastatic triple negative breast cancer with CD44/neuropilin dual molecular targets of multifunctional nanoparticles.
Liang DS; Zhang WJ; Wang AT; Su HT; Zhong HJ; Qi XR
Biomaterials; 2017 Aug; 137():23-36. PubMed ID: 28528300
[TBL] [Abstract][Full Text] [Related]
16. Mussel-Inspired Hyaluronic Acid Derivative Nanostructures for Improved Tumor Targeting and Penetration.
Lee SY; Park JH; Ko SH; Shim JS; Kim DD; Cho HJ
ACS Appl Mater Interfaces; 2017 Jul; 9(27):22308-22320. PubMed ID: 28621523
[TBL] [Abstract][Full Text] [Related]
17. Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment.
Hu G; Chun X; Wang Y; He Q; Gao H
Oncotarget; 2015 Dec; 6(38):41258-74. PubMed ID: 26517810
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial Targeted Doxorubicin-Triphenylphosphonium Delivered by Hyaluronic Acid Modified and pH Responsive Nanocarriers to Breast Tumor: in Vitro and in Vivo Studies.
Liu HN; Guo NN; Wang TT; Guo WW; Lin MT; Huang-Fu MY; Vakili MR; Xu WH; Chen JJ; Wei QC; Han M; Lavasanifar A; Gao JQ
Mol Pharm; 2018 Mar; 15(3):882-891. PubMed ID: 29357260
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticle-Mediated Co-Delivery of Notch-1 Antibodies and ABT-737 as a Potent Treatment Strategy for Triple-Negative Breast Cancer.
Valcourt DM; Dang MN; Scully MA; Day ES
ACS Nano; 2020 Mar; 14(3):3378-3388. PubMed ID: 32083466
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of PEGylated biodegradable nanoparticles for sustained release of docetaxel in triple-negative breast cancer.
Palma G; Conte C; Barbieri A; Bimonte S; Luciano A; Rea D; Ungaro F; Tirino P; Quaglia F; Arra C
Int J Pharm; 2014 Oct; 473(1-2):55-63. PubMed ID: 24992317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
